RBC Capital Reiterates Outperform on Legend Biotech, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Legend Biotech (NASDAQ:LEGN) and maintained a price target of $86.
August 12, 2024 | 4:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Legend Biotech and maintained a price target of $86.
The reiteration of an Outperform rating and a maintained price target of $86 by RBC Capital is a positive signal for investors, suggesting confidence in the company's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100